Global Custom Market Research Reports Provider Company

phone

Pancreatic Cancer - Pipeline Review, H2 2017

  • Published Date: 29 Dec 2017
  • Number of Pages: 2270
  • Category: Healthcare and Medical
  • Country: Global
Pancreatic Cancer - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H2 2017, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 16, 132, 124, 2, 8, 280, 39 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 18, 9, 1, 50 and 8 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct
Table of Contents
Table of Contents 2
Introduction 13
Pancreatic Cancer - Overview 14
Pancreatic Cancer - Therapeutics Development 15
Pancreatic Cancer - Therapeutics Assessment 84
Pancreatic Cancer - Companies Involved in Therapeutics Development 122
Pancreatic Cancer - Drug Profiles 258
Pancreatic Cancer - Dormant Projects 2167
Pancreatic Cancer - Discontinued Products 2188
Pancreatic Cancer - Product Development Milestones 2193
Appendix 2203

List Of Tables


Number of Products under Development for Pancreatic Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pancreatic Cancer - Pipeline by 3-V Biosciences Inc, H2 2017
Pancreatic Cancer - Pipeline by 4P-Pharma SAS, H2 2017
Pancreatic Cancer - Pipeline by 4SC AG, H2 2017
Pancreatic Cancer - Pipeline by AB Science SA, H2 2017
Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2017
Pancreatic Cancer - Pipeline by AbGenomics International Inc, H2 2017
Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2017
Pancreatic Cancer - Pipeline by Aclaris Therapeutics Inc, H2 2017
Pancreatic Cancer - Pipeline by Actuate Therapeutics Inc, H2 2017
Pancreatic Cancer - Pipeline by Adamed Sp z oo, H2 2017
Pancreatic Cancer - Pipeline by Aduro BioTech Inc, H2 2017
Pancreatic Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H2 2017
Pancreatic Cancer - Pipeline by Advantagene Inc, H2 2017
Pancreatic Cancer - Pipeline by AGV Discovery SAS, H2 2017
Pancreatic Cancer - Pipeline by AIMM Therapeutics BV, H2 2017
Pancreatic Cancer - Pipeline by Alissa Pharma, H2 2017
Pancreatic Cancer - Pipeline by Allinky Biopharma, H2 2017
Pancreatic Cancer - Pipeline by Almac Discovery Ltd, H2 2017
Pancreatic Cancer - Pipeline by Altor BioScience Corp, H2 2017
Pancreatic Cancer - Pipeline by Ambrx Inc, H2 2017
Pancreatic Cancer - Pipeline by amcure GmbH, H2 2017
Pancreatic Cancer - Pipeline by American Gene Technologies International Inc, H2 2017
Pancreatic Cancer - Pipeline by Amgen Inc, H2 2017
Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp, H2 2017
Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2017
Pancreatic Cancer - Pipeline by ANP Technologies Inc, H2 2017
Pancreatic Cancer - Pipeline by AntiCancer Inc, H2 2017
Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2017
Pancreatic Cancer - Pipeline by Apexigen Inc, H2 2017
Pancreatic Cancer - Pipeline by Aphios Corp, H2 2017
Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H2 2017
Pancreatic Cancer - Pipeline by Aposense Ltd, H2 2017
Pancreatic Cancer - Pipeline by ARMO Biosciences Inc, H2 2017
Pancreatic Cancer - Pipeline by ArQule Inc, H2 2017
Pancreatic Cancer - Pipeline by Array BioPharma Inc, H2 2017
Pancreatic Cancer - Pipeline by Astellas Pharma Inc, H2 2017
Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2017
Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017
Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2017
Pancreatic Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H2 2017
Pancreatic Cancer - Pipeline by Bayer AG, H2 2017
Pancreatic Cancer - Pipeline by BeiGene Ltd, H2 2017
Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017
Pancreatic Cancer - Pipeline by Berg LLC, H2 2017
Pancreatic Cancer - Pipeline by BerGenBio ASA, H2 2017
Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2017
Pancreatic Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017
Pancreatic Cancer - Pipeline by Bio-Path Holdings Inc, H2 2017
Pancreatic Cancer - Pipeline by BioLineRx Ltd, H2 2017
Pancreatic Cancer - Pipeline by BioMoti Ltd, H2 2017
Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H2 2017
Pancreatic Cancer - Pipeline by Bionomics Ltd, H2 2017
Pancreatic Cancer - Pipeline by BioNTech AG, H2 2017
Pancreatic Cancer - Pipeline by Biouniversa srl, H2 2017
Pancreatic Cancer - Pipeline by BLR Bio LLC, H2 2017
Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Pancreatic Cancer - Pipeline by Boston Biomedical Inc, H2 2017
Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
Pancreatic Cancer - Pipeline by Calithera Biosciences Inc, H2 2017
Pancreatic Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2017
Pancreatic Cancer - Pipeline by Cantargia AB, H2 2017
Pancreatic Cancer - Pipeline by Cantex Pharmaceuticals Inc, H2 2017
Pancreatic Cancer - Pipeline by CARsgen Therapeutics Ltd, H2 2017

List Of Figures


Number of Products under Development for Pancreatic Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

The global market size of Drugs for Metastatic Pancreatic Cancer is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million

View Report

The global market size of Exocrine Pancreatic Insufficiency is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the

View Report

The global market size of Pancreatic Cancer Pipelines is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports